Tanvex Biopharma (TANVF) Financial Statements

6 Followers

Tanvex Biopharma Financial Overview

Tanvex Biopharma's market cap is currently $266.66M. The company's EPS TTM is $-0.046; its P/E ratio is ―; Tanvex Biopharma is scheduled to report earnings on August 12, 2026, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Income Statement
Total Revenue
Gross Profit	$ -19.35M	$ 3.55M	$ 143.00K	$ 0.00	$ 0.00
Operating Income	$ -1.61B	$ -1.60B	$ -2.10B	$ -2.33B	$ -1.95B
EBITDA	$ -1.30B	$ -1.25B	$ -1.87B	$ -2.04B	$ -1.75B
Net Income	$ -1.64B	$ -1.54B	$ -2.10B	$ -2.27B	$ -1.89B
Balance Sheet
Cash & Short-Term Investments	$ ―	$ ―	$ ―	$ ―	$ ―
Total Assets	$ 3.42B	$ 4.71B	$ 4.37B	$ 3.57B	$ 4.48B
Total Debt	$ 1.84B	$ 1.76B	$ 1.46B	$ 342.74M	$ 0.00
Net Debt	$ 1.05B	$ -463.95M	$ -603.96M	$ -2.08B	$ -3.53B
Total Liabilities	$ 2.03B	$ 1.92B	$ 1.75B	$ 542.12M	$ 263.92M
Stockholders' Equity	$ ―	$ ―	$ ―	$ ―	$ ―
Cash Flow
Free Cash Flow	$ -1.43B	$ -1.42B	$ -1.86B	$ -1.99B	$ -1.71B
Operating Cash Flow	$ -1.33B	$ -1.39B	$ -1.79B	$ -1.90B	$ -1.61B
Investing Cash Flow
Financing Cash Flow

Tanvex Biopharma Earnings and Revenue History

Income Statement >

Tanvex Biopharma Debt to Assets

Balance Sheet >

Tanvex Biopharma Cash Flow

Cash Flow >

Tanvex Biopharma Forecast EPS vs Actual EPS

Earnings >